Biomedical optics centers: forty years of multidisciplinary clinical translation for improving human health by Tromberg, Bruce J. et al.
Biomedical optics centers: forty years
of multidisciplinary clinical
translation for improving human
health
Bruce J. Tromberg
R. Rox Anderson
Reginald Birngruber
Ralf Brinkmann
Michael W. Berns
John A. Parrish
Gabriela Apiou-Sbirlea
Bruce J. Tromberg, R. Rox Anderson, Reginald Birngruber, Ralf Brinkmann, Michael W. Berns, John
A. Parrish, Gabriela Apiou-Sbirlea, “Biomedical optics centers: forty years of multidisciplinary clinical
translation for improving human health,” J. Biomed. Opt. 21(12), 124001 (2016),
doi: 10.1117/1.JBO.21.12.124001.
Downloaded From: http://biomedicaloptics.spiedigitallibrary.org/pdfaccess.ashx?url=/data/journals/biomedo/935727/ on 05/19/2017 Terms of Use: http://spiedigitallibrary.org/ss/termsofuse.aspx
Biomedical optics centers: forty years of
multidisciplinary clinical translation for
improving human health
Bruce J. Tromberg,a,* R. Rox Anderson,b,† Reginald Birngruber,b,c,† Ralf Brinkmann,c Michael W. Berns,a
John A. Parrish,d and Gabriela Apiou-Sbirleab,*
aUniversity of California, Irvine, Beckman Laser Institute, 1002 Health Sciences Road East, Irvine, California 92612, United States
bWellman Center for Photomedicine and Harvard Medical School, Massachusetts General Hospital, Research Institute, Department of
Dermatology, 40 Blossom Street, Boston, Massachusetts 02114, United States
cMedical Laser Center Lübeck, Peter Monnik Weg 4, Lübeck 23562, Germany
dCenter for Integration of Medicine and Innovative Technology, 125 Nashua Street, Boston, Massachusetts 02114, United States
Abstract. Despite widespread government and public interest, there are significant barriers to translating basic
science discoveries into clinical practice. Biophotonics and biomedical optics technologies can be used to over-
come many of these hurdles, due, in part, to offering new portable, bedside, and accessible devices. The current
JBO special issue highlights promising activities and examples of translational biophotonics from leading labo-
ratories around the world. We identify common essential features of successful clinical translation by examining
the origins and activities of three major international academic affiliated centers with beginnings traceable to the
mid-late 1970s: The Wellman Center for Photomedicine (Mass General Hospital, USA), the Beckman Laser
Institute and Medical Clinic (University of California, Irvine, USA), and the Medical Laser Center Lübeck at the
University of Lübeck, Germany. Major factors driving the success of these programs include visionary founders
and leadership, multidisciplinary research and training activities in light-based therapies and diagnostics, diverse
funding portfolios, and a thriving entrepreneurial culture that tolerates risk. We provide a brief review of how
these three programs emerged and highlight critical phases and lessons learned. Based on these observations,
we identify pathways for encouraging the growth and formation of similar programs in order to more rapidly and
effectively expand the impact of biophotonics and biomedical optics on human health. © 2016 Society of Photo-Optical
Instrumentation Engineers (SPIE) [DOI: 10.1117/1.JBO.21.12.124001]
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1 Introduction
The annual impact of photonics on the U.S. economy is esti-
mated at $3 trillion, with biophotonics a fast-growing
∼90 billion∕year (worldwide) component.1,2 However, the
present robust commercial activity in biophotonics was, by com-
parison, practically nonexistent in the late 1970s and early 1980s
when the Wellman Center for Photomedicine (WCP, Mass
General Hospital, USA), the Beckman Laser Institute and
Medical Clinic (BLI, University of California Irvine, USA), and
the Medical Laser Center Lübeck (MLL at the University of
Lübeck, Germany) were in formative states. The emergence
of these and other multidisciplinary centers for lasers and optics
in biology and medicine over the past 30 to 40 years is a remark-
able success story that parallels the growth of a variety of medi-
cal photonics technologies spanning from medical lasers to
endoscopes, and optical coherence tomography (OCT) to near-
infrared oximetry. This article is not intended to be a compre-
hensive review of all centers that have played a key role in this
worldwide expansion. Rather we highlight three complementary
programs with roots going back to the mid-late 1970s that
emerged and grew under similar circumstances with colocated
clinical and technology development activities.
Biophotonics and biomedical optics naturally brings together
collaborative multidisciplinary teams who regularly synthesize
concepts from science, engineering, and medicine to develop
new diagnostic and therapeutic methods and devices. Centers
like WCP, BLI, and MLL have played a critical role in providing
space, facilities, and opportunities that have led to remarkably
productive “bench-to-bedside” activity and impact, much of
which began as innovations motivated by important, unsolved
clinical problems. This “translational research” concept has
received significant attention recently, as evidenced in the
USA by the emergence (in 2012) of the National Center for
Advancing Translational Sciences (NCATS) at the National
Institutes of Health (NIH). The goal of this ∼685 million∕
year Institute is to “transform the translational science process
so that new treatments and cures for disease can be delivered to
patients faster.”3 While interest in translation is clearly gaining
worldwide attention, it is instructive to note that MLL, WCP,
BLI, and similar centers have pioneered these activities for more
than 35 years. Biophotonics and biomedical optics naturally
span across domains of basic research, technology development,
commercialization, and clinical translation. The emergence of
commercially successful medical photonics technologies is an
achievement that parallels the growth of these major biophoton-
ics research centers. Understanding aspects of their formation is
essential not only for ensuring the continued clinical translation
of enabling technologies, but for maintaining a robust pipeline
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for generating new ideas, technologies, and workforce that will
advance these activities for the benefit of human health.
WCP, MLL, and BLI are well known for major research and
commercial activities in the development of new optics and pho-
tonics technologies that advance both medical therapeutics and
diagnostics. Examples of therapeutic methods include selective
cutaneous, ophthalmic, and gastrointestinal laser treatments
based on fundamental light–tissue interaction mechanisms
that span photothermal, photochemical, and photomechanical
regimes. Light-based methods are widely used in medicine
with annual commercial sales of phototherapeutic lasers and
similar light sources estimated to be approximately ∼1 B∕year,
creating a much larger overall economic stimulus from medical
services. An important common characteristic of these three
centers is their continued commitment to photomedicine for
improving patient outcomes. This has helped to create a patient
oriented culture in programs that include faculty, staff, and stu-
dents with diverse training in multiple subspecialties of medi-
cine, science, and engineering. Each year, millions of patients
are treated worldwide using biophotonics technologies. In addi-
tion, thousands of patients are treated and enrolled in Institu-
tional Review Board (IRB)-approved protocols by WCP, BLI,
and MLL associated physicians. Optical technologies born in
these centers are now the standard of care for dozens of medical
problems and diseases.
Each center has also pioneered a diverse collection of diagnos-
tic technologies based on the fundamental principles of tissue
spectroscopy and imaging. Optical diagnostics are well suited
for noninvasive and minimally invasive, point-of-care medicine.
The current medical photonics diagnostic market is primarily
based on optical endoscopy, microscopy, near-infrared tissue/
pulse oximetry, perfusion/flow imaging, and OCT. The field of
biophotonics and biomedical optics has been dominated by
remarkable advances in these and related devices over the past
∼25 years. Factors, such as miniaturization, reductions in
barriers-to-access, and the changing healthcare landscape, will
further accelerate the growth and commercialization of diagnostic
medical photonics. In addition, multimodality and hybrid
approaches, spanning from “optics + ultrasound” to “optics +
MRI” are rapidly expanding and expected to achieve clinical
and commercial success in the coming years. Many of these meth-
ods are described in this special issue. BLI, MLL, and WCP have
each played a unique role in fostering translation of these methods
into medical practice, because of their longstanding commitment
to patient outcome and special expertise in identifying new and
clinically impactful applications of emerging technologies.
Examples include advancing OCT in vascular, pulmonary, GI,
and head and neck disease, and using diffuse optics to guide
chemotherapy in breast cancer. This is possible, in part, because
of each center’s rich portfolio and well-established infrastructure
that supports time and effort-intensive translational biophotonics
studies. Overall, WCP, BLI, and MLL have a portfolio of more
than 50 Institutional Review Board (IRB) protocols in optical
diagnostics, and enroll hundreds of patients annually on multiple
investigator-initiated hypothesis-based studies.
2 Centers
2.1 Wellman Center for Photomedicine
TheWellman Center for Photomedicine (WCP) is one of the five
thematic research centers located in Mass General Hospital, the
academic hospital of Harvard Medical School. Founded in 1976
by Harvard Dermatology Professor John A. Parrish MD, WCP
occupies today 38,000 sq. ft, and has 14 core faculty, 12 affili-
ated faculty, and a total of more than 250 professors, staff, and
students working in a multidisciplinary clinical translational
environment. Its name honors Arthur Wellman, a philanthropist
whose wife was successfully treated for disabling psoriasis with
oral psoralen activated by UV-A radiation (PUVA), a new dis-
covery at the time by Dr. Parrish whose early work focused on
human skin photobiology and novel treatments for skin disease
(Fig. 1). Dr. Parrish then recruited physicists, engineers,
pathologists, immunologists and cell biologists to work together
investigating the fundamentals of light–tissue interactions. The
original motivation was to explain and improve treatments that
clinical research had already shown to be effective.
While this ambitious goal was partially achieved, the effort
led to a much wider impact. WCP multidisciplinary research
teams developed a passion for understanding and manipulating
the rich portfolio of molecular changes caused by optical irra-
diation of living tissues. Fascinating photochemical, thermal,
and physical reactions were explored and documented in detail.
Simultaneously, laser, fiber optic, computational, imaging, and
molecular biological technologies were rapidly advancing. In
2004, WCP formally embraced the power of multidisciplinary
research. In contrast to traditional medical departments based
mainly on organ systems, WCP became a nondepartmental MGH
Thematic Center, with Dr. Rox Anderson MD as its new director.
What started as a skin laboratory evolved to be a center con-
tributing high-impact solutions for “the skin and everything in
it.” Laser lithotripsy was developed and launched commercially
for removing urinary stones.4 Other projects such as laser angio-
plasty met with scientific success but practical failure. The con-
cept of selective photothermolysis was introduced,5 leading to
many novel laser treatments for skin, eye, and laryngeal disor-
ders. For the first time, biomedical needs spearheaded the inven-
tion of new laser technologies. Fractional laser treatment was
invented to stimulate skin remodeling, and is fast becoming a
major treatment to normalize scars. The early interest in light-
activated drugs evolved into creative, versatile examples of
Fig. 1 Founding WCP director Dr. John Parrish (left), meets with phi-
lanthropists Arthur (center) and Gullan Wellman (front right) in 1982.
Also present are Thomas B. Fitzpatrick, Chair of the Department of
Dermatology, Harvard Medical School and MGH (second from
left) and Nicolas W. Thorndike, Chairman of MGH Board (second
row, right).
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photodynamic therapy (PDT). Benzoporphyrin derivative, a
drug initially intended for cancer treatment, was repurposed
to become the first approved treatment for retinal macular
degeneration.6 Studies of tissue optics including early math-
ematical models of diffuse radiation transfer were produced,
which set the stage for optical diagnostics. The first laser con-
focal microscope for human use was invented and commercial-
ized,7 now in clinical use. Optical diagnostics became a
sophisticated and diverse field unto itself. The speed, resolution,
and capabilities of OCT, which was invented at MIT almost 30
years ago for retinal imaging, were greatly advanced by WCP
innovations.8 Unprecedented 3-D tissue imaging became pos-
sible through needles, cardiac catheters, swallowed micro-
scopes, and other devices. In addition to the stand-alone optical
diagnostic devices in many medical specialties, we are witness-
ing now their integration with conventional medical imaging,
their use for real-time guidance of surgical and other procedures,
and low-cost simplified versions applicable to solving global
health problems.
The fundamental strength of WCP has always been high-
quality scientific inquiry. For example, a basic understanding of
photothermal processes is what enabled a host of new laser
therapies. Tissue optics and in vivo spectroscopy enabled optical
diagnostics. Photochemistry enabled photodynamic therapies,
including some surprising capabilities now in development.
New themes are emerging at WCP, sometimes beyond the gen-
eral theme of photomedicine. For example, the popular use of
controlled cryotherapy for selective removal of unwanted body
fat is a WCP innovation.
2.2 Beckman Laser Institute and Medical Clinic
Around the same time that Dr. Parrish was working on human
skin photobiology, Dr. Michael W. Berns, PhD, was a professor
of cell biology at the University of California, Irvine (UCI). In
1979, Dr. Berns invited Dr. Arnold O. Beckman, PhD, an inven-
tor-businessman-philanthropist and founder of Beckman
Instruments, Inc. to an “open house” in the Berns lab. At
that time, Dr. Berns had established the first NIH P41
National Biotechnology Research Resource Center for laser
microbeams [the Laser Microbeam Program (LAMP)], a new
technology for cellular microsurgery he had pioneered as a
Cornell University graduate student.9 Lasers and their potential
applications in biology and medicine captured the imagination
of Dr. Beckman and he worked with Dr. Berns to form the
Beckman Laser Institute and Medical Clinic (BLI) in 1982
(Fig. 2). Together they created a BLI nonprofit foundation to
raise money and build a free-standing building on the UCI cam-
pus. This early successful example of a public–private partner-
ship led to the original BLI structure that opened in 1986. In
2003, Dr. Bruce Tromberg, PhD, was appointed BLI director
and Dr. J. Stuart Nelson, MD, medical director. BLI was des-
ignated as a campuswide “special research program” in 2006
but maintains its original Medical School affiliation as a division
in the Department of Surgery.
Although the terminology did not exist at the time, this was
the first dedicated translational facility constructed specifically
for advancing basic science, technology development, and clini-
cal translation of lasers and optics, all under one roof. Several
unique design features that were decades ahead of their time
characterized the building, including open shared spaces; shared
resources for cell biology, biochemistry, histopathology, animal
models, and image processing; and a dedicated laser clinic and
operating room. In addition, a fiber optic network was built
throughout the BLI clinic for delivering light from massive,
water- and power-hungry lasers, the standard of the day, to any
treatment room in the clinic. Although UCI and Lasers were
only 17 and 22 years old, respectively, when BLI was estab-
lished, Dr. Beckman had the foresight to invest significant
resources in a young professor, an unproven university, and an
emerging technology.
The goal of the 1979 NIH LAMP facility was to develop
tools for selectively altering small regions of living cells in
order to study cell and organelle function. As core technologies
continued to develop, new applications of the laser microbeam
evolved, particularly in the area of gradient force optical trap-
ping, chromosome microdissection, laser-induced gene trans-
fection, and nonlinear laser microbeams.10 Although rooted
in basic science, the perceived clinical and commercial potential
of LAMP technologies inspired Dr. Beckman and Dr. Berns to
establish the BLI, a crucial step that accelerated the clinical
translation of lasers and optics.
Today the BLI is a 37,000 sq.-ft free-standing facility with 17
faculty and more than 200 professors, staff, and students from
more than 10 science, engineering, and clinical departments on
the UC Irvine campus. Clinical applications emerged within BLI
in the late 1980s, particularly in the areas of PDT for cancer and
dynamic cooling technology for cutaneous laser surgery.11
Several important new technologies, biomedical applications,
and clinical studies appeared during subsequent years, including
laser microbeam assisted in vitro fertilization technologies,10
Doppler OCT for imaging blood flow,12 diffuse optical methods
for imaging perfusion and metabolism in thick tissues,13 and
multimodality endoscopic tomographies.14 Virtual photonics
technologies also emerged, an effort entirely dedicated to bio-
photonics modeling and computation for simulating and visual-
izing light propagation in biological tissues.
2.3 Medical Laser Center Lübeck
In Europe in 1975 Dr. Franz Hillenkamp PhD, a young biomedi-
cal engineer who led the Laboratory for Coherent Optics at the
“Gesellschaft für Strahlen- und Umweltforschung,” a National
Laboratory for Radiation and Environmental Research in
Munich, Germany, introduced a Medical Laser Applications
Laboratory. This center provided standardized laser- and optical
delivery-technology together with extended animal facilities for
Fig. 2 In 1982 Dr. Arnold O. Beckman (left) presented Dr. Michael W.
Berns, founding BLI director, with the first check to establish the
Beckman Laser Institute at UC Irvine.
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application oriented in vitro and in vivo studies in laser medi-
cine. Medical scientists from ophthalmology, gastroenterology,
urology, neurosurgery, and oral surgery performed studies in the
areas of photocoagulation and photodisruption in ophthalmology,
laser-induced hemostasis in gastric ulcers, laser therapy of blad-
der tumors, and laser bone surgery. Dr. Alfons Hofstetter MD,
the urologist in this research group, left Munich and became
Chairman of Urology at the University of Lübeck in 1984. Much
like Dr. Parrish and Dr. Berns whose early research seeded the
growth of larger centers, Dr. Hofstetter’s work initiated the foun-
dation of the Medical Laser Center Lübeck (MLL—formal
“Medizinisches Laserzentrum Lübeck GmbH”). The MLL,
funded by the German state of Schleswig-Holstein as a separate,
but university-associated R&D Institution at the University of
Lübeck, opened in 1986.
The intention of MLL from the very beginning was to intro-
duce, launch, and establish laser technologies in medicine. Core
expertise in high-power IR-lasers, short- and ultra-short pulse-
lasers, miniaturized solid-state lasers, etc. was leveraged by
interdisciplinary and transinstitutional collaborations between
research institutions, industry, and hospitals. In order to facili-
tate translation of research to clinical practice, the MLL was
founded as a nonprofit limited liability company (GmbH) with
seven associates, two universities including the leading state
hospital, four biomedical companies, and the Hanseatic city of
Lübeck. Physicists, a biologist, engineers, and physicians were
hired and a research building was constructed together with a
guesthouse for collaborators and participants of conferences and
training courses. Application-oriented R&D-projects in urology
(lithotripsy), tumor therapy (PDT) quickly emerged.
In 1991, Dr. Reginald Birngruber PhD, MD became the
Chief Executive Officer (CEO) and Chief Research Officer
(CRO) of the MLL and research initiatives in ophthalmology
(picosecond photodisruption, PDT, microphotocoagulation) and
cardiovascular laser therapy (laser angioplasty) were added,
always in close collaboration with clinicians and various laser
companies. Understanding mechanisms of light–tissue interac-
tion and photothermal tissue effects became crucial research
activities that helped drive the development of novel and
economically successful technologies. Examples include, math-
ematical modeling of temperature profiles, thermal denaturation
kinetics,15 and nonlinear processes in pulsed laser tissue abla-
tion.16 New laser systems like the Alexandrite solid-state
laser and high-power picosecond lasers were modified and
adapted to solve specific clinical problems. A mutual collabo-
ration with the Wellman Center for Photomedicine in Boston
resulted in the invention and development of new medical
laser applications, including carrier-mediated PDT to make
age-related macula degeneration (AMD) a treatable disease for
the first time17 and selective retina therapy for precise treatments
of various early stage retinal diseases.18 Several medical laser
devices were commercialized in collaboration with MLL’s part-
ners, for example, the first feedback controlled laser-lithotriptor
Lithognost,19 several PDT laser devices for ophthalmology, and
a miniaturized handheld IR-laser scalpel for trabeculectomy.
In 2005, the Institute of Biomedical Optics (BMO) was
formed out of the MLL-research teams and became part of the
University of Lübeck. BMO was created to offer new courses in
biomedical optics, photonics, optical imaging and laser medi-
cine to educate and prepare the next generation for emerging
technologies in optical life sciences. BMO, now an academic
institution, hosts undergraduate and graduate students and can
conduct research in all aspects of optics in medicine and biol-
ogy, supported by more traditional state and federal funding.
MLL kept its status as a nonprofit R&D company financially
independent and supported solely by project funds derived
from clinical, translational and applied research in collaboration
with clinical and industrial partners (Fig. 3). After Dr.
Birngruber retired in 2010, Dr. Alfred Vogel PhD became the
Director of the BMO, and Dr. Ralf Brinkmann PhD took over
MLL as its CEO in 2011.
Today, MLL and BMO have 10 faculty and more than 80
professors, staff, and students working in the interdisciplinary
field of biophotonics. Therapeutic laser applications are still the
strongest MLL focus area. Activities in imaging and in vivo
diagnostics, metrology, laser material processing and prototype
development, and management of clinical studies continue to
expand. A unique feature of MLL as a limited liability company
is that it can legally register prototypes according to the European
medical product law and perform proof-of-concept clinical tri-
als. This strong partnership between a university institute, a uni-
versity hospital, and a highly flexible nonprofit R&D company,
sharing infrastructure and personnel, but being formally inde-
pendent, has been proven highly successful. Importantly, the
MLL with its own lean administrative structure and low over-
head can act quickly and adapt to short-term industrial tasks,
but also serve as a reliable partner in long-term public funded
programs.
3 Common Features for all Centers
What common strategies foster “translational” research in these
centers, all the way from early discovery, through development,
commercialization, and adoption in medical practice? First, all
are either located in or closely affiliated with academic medical
centers and medical schools. In contrast to traditional medical,
engineering, and basic science departments based mainly on
organ systems or specific disciplines, all are transdepartmental
centers with faculty, staff, and students who have different back-
grounds and perspectives. Intellectual diversity, in turn, plays a
key role in the second major common feature: each center is
dedicated to the idea that optics and photonics technologies can
be used to advance science for solving practical problems that
impact human health. With multidisciplinary clinics and physi-
cians embedded in each center, collaborating scientists and engi-
neers are able to develop a “translational vision” focused on
identifying and solving important clinical problems. In addition,
Fig. 3 Dr. Reginald Birngruber (center), MLL founding CEO, meets
with current CEO Ralf Brinkmann (left) and Annette Schavan (right
front), German Minister of Research and Education, in 2006.
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there are unique resources available to help investigators
develop IRB-approved clinical protocols and enroll patients on
investigational studies that use biophotonics technologies. This
culture is strongly reinforced by the emphasis in each center on
developing new medical laser therapies. Millions of people have
benefited from treatments launched directly from WCP, BLI,
and MLL. Opportunities to continue this activity and develop
new approaches including image-guided therapies are consid-
ered to be highly motivating challenges.
Although located in different regions spanning private
(WCP), public (BLI), and mixed (MLL) operational models,
each has embraced supporting high-risk, high-reward research.
This fourth common element is made possible, in part, by hav-
ing a diverse funding portfolio that includes a balance of extra-
mural peer-reviewed grants that are restricted to specific
projects, and more flexible sources of exploratory funding
derived from royalty revenues, philanthropy, and other commer-
cialization activities. These funds can be used to seed emerging
ideas, initiate new lines of study, and develop proof-of-concept
technologies and prototypes. Leveraging with collaborating
departments and schools has also proven successful. In the
case of WCP and BLI, US Department of Defense (DOD) sup-
port is an important mechanism that is synergistic with NIH
since it is aimed to solve military medical problems using photo-
medicine strategies. The problem-motivated, get-the-job-
done culture of DOD is a powerful stimulus for hatching and
developing new solutions for combat medical problems. Many
of these can be “dual use,” helping both civilian and military
patients. Importantly, the military Medical Photonics Program
administered by the Air Force Office of Scientific Research
(AFOSR) has had enormous impact on the growth of biopho-
tonics and biomedical optics worldwide, both through ongoing
programs at these centers, and via direct support of research at
other institutions. Despite the diversity and growth of research
support at these centers, funding still limits the volume and rate
of research.
In summary, MLL, WCP, and BLI are privileged to be in
problem-rich medical environments with academically and
intellectually diverse faculty, students, and staff. Each has a
strong tradition of problem solving, innovation, and technology
development that has contributed to the worldwide growth of
medical photonics technologies and translational research. With
continued global expansion of photonics technologies, scientists
and engineers will have even more opportunities to partner with
physicians and patients to ensure that new discoveries are rap-
idly translated into cost-effective strategies for curing and pre-
venting disease. Biophotonics centers have a well-established
history for accelerating this process, making their unique inter-
disciplinary problem-solving mission even more compelling and
essential than ever.
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